News Archives - Page 3 of 8 - Buhlmann Diagnostics Corp

Category: News

Buhlmann – Next Generation Food Allergy Drug Development Summit

Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused on enhancing the food allergy drug development approach. Flow CAST® is the standardized, proven & assessable Basophil Activation Test. An accurate biomarker of an allergic reaction… in a vial. BUHLMANN Allergy Assay Offering Diagnosis of
Continue Reading

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

Continue Reading

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Use of basophil activation in oral immunotherapy

An outstanding research paper was published in the top rated Journal of Allergen and Clinical Immunology which evaluated the performance of basophil activation as a biomarker in monitoring clinical efficacy of oral peanut immunotherapy in a clinical trial.

Continue Reading

CALEX Cap Promotion

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design
Continue Reading

Flow CAST- Assay Overview Video

Flow CAST®: Research Use Only in the US. Not for diagnostic procedures. Health Canada License:101781 BÜHLMANN Flow CAST® and Basophil Activation (BAT): Basophil Activation Tests (BAT) have been extensively studied as in vitro functional assays and have demonstrated superior accuracy as compared to other blood tests for various allergies (1).  BÜHLMANN  provides a broad range of
Continue Reading

BUHLMANN Debriefing- EuroMedLab 2019

BÜHLMANN Educational Workshop at EuroMedLab 2019 The BÜHLMANN Educational Workshop at EuroMedLab 2019, focused on optimizing workflow for fecal calprotectin testing was a great success.  This workshop offered insightful presentations from three laboratories discussing the process of stool sample pre-analytics and how they worked to find a solution to cope with continuously increasing test numbers.
Continue Reading

BÜHLMANN fCAL® turbo Success Story- Freeman Hospital, Newcastle

The Benefits of Switching to BÜHLMANN Assay for Calprotectin Testing Dr. Elodie Hanon, Prinicpal Clinial Scientist at the Freeman Hospital, Newcastle, UK (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article "We went live with the fCAL turbo in March 2018, and there really have been no issues. The turn-around time
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX®Cap Stool Preparation Device

BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® turbo Automated Calprotectin Test

BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 26, 2019: BÜHLMANN Laboratories AG, is proud to announce it received United States Food and Drug
Continue Reading